File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Lyso-thermosensitive liposomal doxorubicin: An adjuvant to increase the cure rate of radiofrequency ablation in liver cancer

TitleLyso-thermosensitive liposomal doxorubicin: An adjuvant to increase the cure rate of radiofrequency ablation in liver cancer
Authors
Keywordshepatocellular carcinoma
lyso-thermosensitive liposomal doxorubicin
radiofrequency ablation
Issue Date2011
PublisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/fon
Citation
Future Oncology, 2011, v. 7 n. 8, p. 937-945 How to Cite?
AbstractHepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. No more than 30% of HCC patients are considered suitable for curative treatment because of tumor size and severity of liver impairment, among other factors. Radiofrequency ablation (RFA) monotherapy can cure small (<3 cm) HCC tumors. An adjuvant that interacts synergistically with RFA might enable curative therapy for many HCC patients with lesions >3 cm. Lyso-thermosensitive liposomal doxorubicin (LTLD) consists of the heat-enhanced cytotoxic doxorubicin within a heat-activated liposome. LTLD is infused intravenously prior to RFA. When heated to >39.5° ,°C, LTLD releases doxorubicin in high concentrations into the tumor and the tumor margins. The RFA plus LTLD combination has shown a statistically significant dose-response effect for time to treatment failure in a Phase I trial in which most subjects (62.5%) had tumors >3 cm. RFA plus LTLD is currently being evaluated in a 600-patient randomized, double-blind, dummy-controlled trial. © 2011 Future Medicine Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/139747
ISSN
2015 Impact Factor: 2.129
2015 SCImago Journal Rankings: 0.957
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorBorys, Nen_HK
dc.date.accessioned2011-09-23T05:55:11Z-
dc.date.available2011-09-23T05:55:11Z-
dc.date.issued2011en_HK
dc.identifier.citationFuture Oncology, 2011, v. 7 n. 8, p. 937-945en_HK
dc.identifier.issn1479-6694en_HK
dc.identifier.urihttp://hdl.handle.net/10722/139747-
dc.description.abstractHepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. No more than 30% of HCC patients are considered suitable for curative treatment because of tumor size and severity of liver impairment, among other factors. Radiofrequency ablation (RFA) monotherapy can cure small (<3 cm) HCC tumors. An adjuvant that interacts synergistically with RFA might enable curative therapy for many HCC patients with lesions >3 cm. Lyso-thermosensitive liposomal doxorubicin (LTLD) consists of the heat-enhanced cytotoxic doxorubicin within a heat-activated liposome. LTLD is infused intravenously prior to RFA. When heated to >39.5° ,°C, LTLD releases doxorubicin in high concentrations into the tumor and the tumor margins. The RFA plus LTLD combination has shown a statistically significant dose-response effect for time to treatment failure in a Phase I trial in which most subjects (62.5%) had tumors >3 cm. RFA plus LTLD is currently being evaluated in a 600-patient randomized, double-blind, dummy-controlled trial. © 2011 Future Medicine Ltd.en_HK
dc.languageengen_US
dc.publisherFuture Medicine Ltd. The Journal's web site is located at http://www.futuremedicine.com/loi/fonen_HK
dc.relation.ispartofFuture Oncologyen_HK
dc.subjecthepatocellular carcinomaen_HK
dc.subjectlyso-thermosensitive liposomal doxorubicinen_HK
dc.subjectradiofrequency ablationen_HK
dc.titleLyso-thermosensitive liposomal doxorubicin: An adjuvant to increase the cure rate of radiofrequency ablation in liver canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1479-6694&volume=7&issue=8&spage=937&epage=945&date=2011&atitle=Lyso-thermosensitive+liposomal+doxorubicin:+an+adjuvant+to+increase+the+cure+rate+of+radiofrequency+ablation+in+liver+cancer-
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2217/fon.11.73en_HK
dc.identifier.pmid21823888-
dc.identifier.scopuseid_2-s2.0-80051741377en_HK
dc.identifier.hkuros192495en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80051741377&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume7en_HK
dc.identifier.issue8en_HK
dc.identifier.spage937en_HK
dc.identifier.epage945en_HK
dc.identifier.isiWOS:000294544300006-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.scopusauthoridBorys, N=26537167700en_HK
dc.identifier.citeulike9663662-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats